Epidemiological and biologic profile of breast cancer in Fez-Boulemane, Morocco;Le profil épidémiologique et biologique du cancer du sein à Fès-Boulemane (Maroc)

Eastern Mediterranean Health Journal

Volumn 17, Issue 12, 2011, Pages 930-936

  Abbass, F ^a   Bennis, S ^b   Znati, K ^c   Akasbi, Y ^d   Amrani, J K ^a   El Mesbahi, O ^d   Amarthi, A ^c  

^a SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

^b SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

^c Service d'Anatomie Pathologique   (Morocco)

^d HASSAN II UNIVERSITY HOSPITAL   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855215476     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2011.17.12.930     Document Type: Article

References (23)

1. Molinié F et al. Incidence et facteurs pronostiques des cancers du sein découverts au cours et en dehors du programme de dépistage organisé en Loire-Atlantique (1991-2002) [Incidence and prognostic factors of breast cancer diagnosed within and outside the organised screening program in the department of Loire-Atlantique (1991-2002)]. Revue d'Épidémiologie et de Santé Publique, 2008, 56:41-49.
2. Dajani YF, Al-Jitawi SA. A study of 405 breast tumors in Jordanians using the Revised WHO classification. Tropical and Geographical Medicine, 1987, 39:182-186.
3. Abalkail AA et al. The role of young population structure in determining age distribution of breast cancer in Jordan. Journal of the Bahrain Medical Society, 2003, 15:28-33.
4. Lamy PJ et al. Classification moléculaire des cancers du sein: utilité en clinique [Molecular classification of breast cancers: clinical utility]. Médecine nucléaire, 2010, 34(1):32-43.
5. Osborne CK et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer, 1980, 46(Suppl.):2884-2888.
6. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Seminars in Oncology, 1988, 15(Suppl. 1):20-25.
7. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1992, 339:71-85.
8. Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clinical Leadership & Management Review, 2003, 17:333-340.
9. Belkacémi Y et al. Intérêt des classifications moléculaires pour prédire la rechute locale et la diffusion métastatique des cancers du sein [The use of breast cancer subtype classification to predict local and distant recurrence. A review]. Cancer Radiothérapie, 2008, 12:2577-2583.
10. Engel J et al. The process of metastasisation for breast cancer. European Journal of Cancer (Oxford, England), 2003, 39:1794-1806.
11. Fédération nationale des Centres de Lutte contre le Cancer (FNCLCC). Comprendre le cancer du sein. Guide d'information et de dialogue à l'usage des patientes et de leurs proches, mise à jour 2002 [Understanding breast cancer. An information and dialogue guide for patients and their families, 2002 update]. Paris, Fédération nationale des Centres de Lutte contre le Cancer, Collection SOR SAVOIR PATIENT (Standards, Options et Recommandations pour le Savoir des Patients), 2002:1-160.
12. Grosclaude P et al. Survival of women with breast cancer in France: variation with age, stage and treatment. Breast Cancer Research and Treatment, 2001, 70:137-143.
13. Tavassoli FA, Devilee P, eds. Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC Press, 2003 (World Health Organization classification of tumours, No. 4).
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991, 19:403-410.
15. Wolff AC et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology, 2007, 25:118-145.
16. Parise C et al. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone (RP), and the human epidermal growth factor receptor2 (Her2) among women with invasive breast cancer subtypes in California 1999-2004. Breast Journal, 2009, 15:593-602.
17. Grann VR et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 2005, 103:2241-2251.
18. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research, 2007, 9:R6.
19. Parise C, Bauer K, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Critical Reviews in Oncology/ Hematology, 2010, 76(1):44-52.
20. Almasri NM, Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Research, 2005, 7:R598-R604.
21. Blamey RW et al. ONCOPOOL-a European database for 16,944 cases of breast cancer. European Journal of Cancer, 2010, 46:56-71.
22. Ernst MF et al. Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Research and Treatment, 2002, 76:19-25.
23. Gill PG et al. Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast, 2004, 13:15-22.